# Kaigene Enters into Exclusive Global Licensing Agreement with Celltrion for Next-Generation Anti-APRIL Antibody KG013

- Source: PR Newswire
- Published: 2026-10-22T13:00:00+00:00
- Category: Business
- Original: https://www.prnewswire.com/news-releases/kaigene-enters-into-exclusive-global-licensing-agreement-with-celltrion-for-next-generation-anti-april-antibody-kg013-302916925.html
- Canonical: https://groundlevelnews.com/story/kaigene-enters-into-exclusive-global-licensing-agreement-with-celltrio-145e3f/

Key Highlights Kaigene grants Celltrion exclusive worldwide development and commercialization rights to KG013, while retaining an option to participate in co-marketing in South Korea under the agreement. KG013 is a next-generation, half-life-extended, fully human anti-APRIL monoclonal...

_Ground Level News shows a short summary only; the full article and all rights belong to PR Newswire._